Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16) [PDF]
BMC Cancer, 2023 Purpose To explore the outcome and prognostic factors between inv(16) and t(8;21) disrupt core binding factor (CBF) in acute myeloid leukemia (AML). Methods The clinical characteristic, probability of achieving complete remission (CR), overall survival ...
Kun-yin Qiu +6 more
doaj +2 more sources
Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance [PDF]
Nature Communications, 2021 miR-126 is highly expressed in inv(16) Acute myeloid leukemia (AML) but its role is unclear. Here, the authors show that the aberrant expression of miR-126 in inv(16) AML is directly due to the CBFB-MYH11 fusion gene and that it can promote AML ...
Lianjun Zhang +24 more
doaj +2 more sources
Acute myeloid leukemia with inv(16)(p13.1q22) and deletion of the 5’MYH11/3’CBFB gene fusion: a report of two cases and literature review [PDF]
Molecular Cytogenetics, 2020 Background Abnormalities of chromosome 16 are found in about 5–8% of acute myeloid leukemia (AML). The AML with inv(16)(p13.1q22) or t (16;16)(p13.1;q22) is associated with a high rate of complete remission (CR) and favorable overall survival (OS) when ...
Lili Lv, Jingwei Yu, Zhongxia Qi
doaj +2 more sources
Faggot cells in therapy‐related acute myeloid leukemia with inv(16) [PDF]
Clinical Case Reports, 2021 Faggot cells are an uncommon finding in nonacute promyelocytic leukemia, even rarer when observed in mature granulocytic cells. Inv(16) should be dismissed when pre‐eosinophilic granulation and faggot neutrophils are observed.
Ana Vega González de Viñaspre +5 more
doaj +2 more sources
Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia [PDF]
Frontiers in Oncology, 2018 Acute myeloid leukemia (AML) is a collection of hematologic malignancies with specific driver mutations that direct the pathology of the disease. The understanding of the origin and function of these mutations at early stages of transformation is ...
John Anto Pulikkan +1 more
doaj +2 more sources
Disrupting the CBFβ-SMMHC-RUNX1 oncogenic protein–protein interaction in inv(16) AML: from fusion biology to targeted therapy [PDF]
Discover OncologyCore-binding factor (CBF) leukemias, including inv(16) AML, involve RUNX1/CBFβ chromosomal rearrangements that generate oncogenic fusion proteins. In inv(16) AML, the CBFβ–SMMHC fusion (CBFB–MYH11) dominantly perturbs RUNX1 by sequestering it in aberrant,
Emadeldin M. Kamel +6 more
doaj +2 more sources
Rare type I CBFβ/MYH11 fusion transcript in primary acute myeloid leukemia with inv(16)(p13.1q22): a case report [PDF]
Brazilian Journal of Medical and Biological Research, 2021 Inv(16)(p13.1q22) in acute myeloid leukemia (AML) is a common chromosomal abnormality. It leads to the core-binding factor ß-subunit (CBFβ)/smooth muscle myosin heavy chain 11 (MYH11) fusion gene.
Wenyi Zhang +5 more
doaj +2 more sources
Genome-wide binding of transcription factors in inv(16) acute myeloid leukemia [PDF]
Genomics Data, 2014 The inv(16) translocation is associated with 5% of AML cases and gives rise to expression of the oncofusion protein CBFβ-MYH11. Although different molecular mechanisms for the oncogenic activity of this fusion protein have been proposed these were mostly
A. Mandoli, K. Prange, J.H.A. Martens
doaj +2 more sources
Constitutional pericentric inversion of chromosome 16, inv(16)(p13.1q22), mimicking acute myeloid leukemia [PDF]
eJHaem, 2022 Shuji Ozaki +6 more
doaj +2 more sources
PB1836: LOSS OF HETEROZYGOSITY IN AML PATIENTS WITH INV(16) [PDF]
HemaSphere, 2023 Dmitry Bessmertniy +4 more
doaj +2 more sources